Skip to main content

Table 3 Early pregnancy endogenous hormones and breast cancer risk for a doubling of hormone concentration, by ER/PR status: Northern Sweden Maternity Cohort

From: Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case–control study in the Northern Sweden Maternity Cohort

  Overall ER–/PR– ER+/PR+ p het
Estradiol 220/404 50/89 152/282  
1.19 (0.94–1.50) 1.35 (0.78–2.32) 1.08 (0.81–1.43) 0.18
Free estradiol 210/374 49/86 143/258  
1.02 (0.80–1.29) 1.09 (0.59–2.02) 0.95 (0.72–1.27) 0.31
Estrone 222/410 50/90 154/286  
1.08 (0.89–1.30) 1.20 (0.77–1.88) 0.97 (0.78–1.22) 0.13
Testosterone 221/407 50/90 153/283  
1.33 (1.02–1.74) 0.82 (0.47–1.43) 1.57 (1.13–2.18) 0.05
Free testosterone 211/377 49/87 144/260  
1.08 (0.88–1.33) 0.66 (0.40–1.08) 1.31 (1.02–1.68) <0.01
Progesterone 221/406 50/90 153/282  
0.94 (0.67–1.34) 1.61 (0.77–3.36) 0.64 (0.41–1.00) 0.01
SHBG 212/384 49/89 145/264  
1.19 (0.95–1.50) 1.47 (0.90–2.40) 1.05 (0.80–1.38) 0.10
  1. Data presented as number of cases/controls and ORlog2 (95% CI)
  2. Conditional logistic regression controlling for gestational age at blood collection (continuous). p het between ER+/PR+ and ER–/PR– breast cancer subtypes assessed using a likelihood ratio test comparing models assuming the same association between the hormones and breast cancer overall to one assuming different associations by subtype
  3. CI confidence interval, ER estrogen receptor, OR odds ratio, PR progesterone receptor, SHBG sex hormone binding globulin